1440P Final Top-Line Results of the BGBC008 Phase II, Multicenter Study of Bemcentinib and Pembrolizumab (bem+pembro) in Second-Line (2L) Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer (NSCLC) (NCT03184571)
Annals of Oncology(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined